Prostate Health: A Nutritional and Natural-Health Reference
1. Definition and Overview
The prostate is a small gland in men that helps make semen. Located just below the bladder in front of the rectum, it wraps around the tube that carries urine and semen out of the body. When men are in their 20s, the normal prostate is about the size of a walnut. By the time a man is 40 the prostate may have grown slightly larger, and by age 60, the prostate is often the size of a lemon.
Prostate changes and conditions that are common in men include inflammation (prostatitis), enlarged prostate (benign prostatic hyperplasia, or BPH), and prostate cancer. Prostate cancer is the second most common type of cancer that affects males. Inflammation (prostatitis) causes the tissues in and around the prostate to become swollen and tender; it is the most common urinary system issue in males younger than 50 and the third most common urinary system issue in males older than 50.
2. The Three Principal Prostate Conditions
2.1 Benign Prostatic Hyperplasia (BPH)
Benign prostatic hyperplasia (BPH), also called an enlarged prostate, is an overgrowth of prostate tissue. Its name comes from benign (not cancer) and hyperplasia, which means there are an increased number of cells in the prostate gland. BPH commonly refers to excessive growth of the gland that usually occurs after age 50; it can double or triple in mass during the latter decades of life. BPH is not cancer. Almost all males develop some degree of prostate enlargement as they age.
As the prostate expands in size, it effectively pinches off the urethra (the tube carrying urine from the bladder to the penis), making the muscular walls of the bladder have to work harder and causing problems with urination. About half of BPH cases are asymptomatic, but some men will experience problems.
2.2 Prostatitis
Prostatitis refers to an inflamed prostate, and there are two main types: acute prostatitis and chronic prostatitis. Acute prostatitis is caused by an infection, usually by bacteria, and results in the sudden onset of painful urination, a small stream, and often fever and chills. Chronic prostatitis, also known as chronic pelvic pain syndrome, is a less well-defined condition. Its symptoms include persistent or recurrent pelvic discomfort, pain or burning with urination, an increased urge to urinate, and difficulty emptying the bladder.
2.3 Prostate Cancer
As with other cancers, prostate cancer is the abnormal growth of cells. Globally, prostate cancer (PCa) is the second most common cancer, with the highest incidence in North and South America, Europe, Australia, and the Caribbean. Early-stage prostate cancer does not usually cause symptoms. However, locally advanced prostate cancer may cause urinary symptoms including blood in the urine or semen, or pain in the back, hips, or pelvis that does not go away.
A 2019 systematic review and meta-analysis published in PMC examined the epidemiological relationships among the three conditions. Among 27 studies describing the association between prostatitis and prostate cancer, the pooled odds ratio was 1.72 (95% CI 1.44โ2.06). Twenty-one studies presented significant evidence about the relation between BPH and prostate cancer (OR=2.16, 95% CI 1.75โ2.88). The authors note that high heterogeneity (Iยฒ > 90%) limits causal interpretation.
3. Body Systems Involved
Prostate health intersects several physiological systems:
- Reproductive system: The prostate contributes fluid to semen and is part of the male reproductive tract.
- Urinary system: Benign prostatic hyperplasia can lead to obstructive and bothersome lower urinary tract symptoms (LUTS), and prostate gland enlargement can block the flow of urine out of the bladder, which can cause bladder, urinary tract, or kidney problems.
- Endocrine system: Androgen hormones โ particularly testosterone and its more potent derivative dihydrotestosterone (DHT) โ drive prostate cell proliferation and are central to both BPH and prostate cancer biology.
- Immune and inflammatory systems: Data from the Prostate Cancer Prevention Trial found that markers of systemic inflammation (in this case C-reactive protein) or lower levels of soluble receptors that bind inflammatory cytokines (such as TNF and IL-6) increased BPH risk.
4. Contributing and Associated Risk Factors
4.1 Non-Modifiable Factors
Risk factors for prostate cancer include age, family history, and genetic predisposition. Age increases the risk of prostate problems, such as BPH and prostate cancer. A 2024 umbrella review in PLOS Medicine (PMC10980219) systematically searched meta-analyses and Mendelian randomization studies through September 2023 to evaluate factors modifying prostate cancer risk. Participants across included qualitative studies consistently identified age, family history, genetics, and race/ethnicity as risk factors for prostate cancer.
4.2 Modifiable and Lifestyle Factors
Additional factors that may influence prostate cancer risk include smoking, diet, physical activity, specific medications, and occupational factors.
Obesity: Obesity is associated with a higher risk of death from prostate cancer based on the findings of multiple included studies in a systematic review. A 2023 systematic review published in BJUI Compass (Dovey et al., Mount Sinai Health System) concluded that the mostly indolent natural history of prostate cancer provides an opportunity for men to explore the benefits of lifestyle interventions, and current evidence suggests appropriate changes in lifestyle including diet, physical activity, and stress reduction with or without dietary supplements may improve both disease outcomes and patient's mental health.
Inflammation: PCa has several well-established risk factors; however, the influence of lifestyle factors remains under investigation. Chronic prostatic inflammation has been proposed as a contributor to both BPH progression and carcinogenesis, though establishing causality remains challenging.
5. Nutrients, Herbs, and Natural Ingredients
The following sections separate traditional use โ referring to historical and ethnobotanical practices โ from scientific evidence derived from human clinical studies, systematic reviews, and well-designed trials. Where evidence comes only from laboratory or animal work, this is explicitly noted.
5.1 Saw Palmetto (Serenoa repens)
Traditional Use: The berries of the saw palmetto palm, native to the southeastern United States, have been used by Native American communities for nutritional and urogenital purposes for centuries. In the 19th and early 20th centuries, saw palmetto berry extracts appeared in European and American eclectic medicine formularies as a tonic for the male reproductive and urinary systems. Lipophilic extracts of the berry became widely adopted in European phytotherapy โ particularly in France and Germany โ for lower urinary tract symptoms during the latter decades of the 20th century.
Proposed Mechanisms: Saw palmetto has been proposed to inhibit 5-alpha-reductase (the enzyme that converts testosterone to dihydrotestosterone), possess anti-inflammatory activity, and exert anti-proliferative effects on prostate epithelial cells, though the relative importance of these mechanisms in humans remains debated.
Scientific Evidence: A 2023 review of 27 studies on saw palmetto in men with BPH found that this herb, when administered alone, provides little or no benefit for BPH symptoms. There is not enough evidence to determine whether saw palmetto is useful for other health purposes, and more studies are needed before definitive conclusions can be made.
Two clinical trials funded by the National Institutes of Health, both of which evaluated saw palmetto alone, were included in this review. One tested a standard dose of saw palmetto; the other tested increasing doses, up to three times the usual dose. In both studies, saw palmetto did not improve BPH symptoms.
Although several small studies have suggested modest benefit of saw palmetto for treating symptoms of BPH, a large study evaluating high doses and a Cochrane review found that saw palmetto was not more effective than placebo for treatment of urinary symptoms related to BPH. However, a recent systematic review and meta-analysis found that Serenoa repens had the same effect as tamsulosin in treating BPH in terms of International Prostate Symptom Score, quality of life, maximum flow rate, postvoid residual volume, and PSA โ with the exception of prostate volume.
A 2022 review of five studies on saw palmetto for chronic prostatitis/chronic pelvic pain syndrome did not find a significant benefit of the herb in patients with this condition.
A 2014 randomized trial of 225 men with lower urinary tract symptoms and BPH examined combination therapy between saw palmetto, lycopene, and selenium plus tamsulosin versus single therapies. The findings suggest that a combination therapy of saw palmetto, lycopene, selenium, and tamsulosin is more effective than single therapies in improving International Prostate Symptom Score and increasing maximum urinary flow rate. However, this combination design does not permit attribution of benefit to any single component.
Evidence strength: Overall negative to neutral for saw palmetto alone based on the best-quality trials. Some signals in combination therapy require further investigation. NCCIH characterizes it as "probably not helpful" for BPH symptoms as a standalone agent.
5.2 Pygeum (Pygeum africanum / Prunus africana)
Traditional Use: Pygeum africanum, also known as the African plum tree, is an evergreen tree native to the Central and South American mountains, the Madagascar and Comoros islands, and the Gulf of Guinea. Extracts from the bark of the tree have traditionally been used for inflammation, kidney diseases, urinary problems, prostate gland inflammation, and other uses.
Scientific Evidence: There is some limited evidence that Pygeum africanum may improve some symptoms of BPH, including urinary symptoms, flow parameters, spermogram, and quality of life. A 2015 review of clinical studies found some such evidence. However, these studies were of short duration, performed on small groups of patients, and had varied evaluation methods and varied formulations.
A 2002 meta-analysis indicated that Pygeum africanum is more effective than placebo in relieving BPH-related symptoms. A 2002 Cochrane review of 18 randomized controlled trials involving 1,562 men with BPH concluded that a standardized preparation of Pygeum africanum may be a useful treatment option for men with lower urinary symptoms consistent with BPH.
In a report on Prunus africana from the Committee on Herbal Medicinal Products of the European Medicines Agency, based on data from clinical reviews involving a total of 1,310 patients and daily doses of 75โ200 mg of lipophilic extracts with treatment periods from 15 to 120 days, it was concluded that Pygeum bark improved the symptoms and objective measures of BPH and was well tolerated.
Preclinical research suggests additional mechanisms. The anti-cancer potential of Pygeum africanum has been tested both in vitro (PC-3 and LNCaP cells) and in vivo (TRAMP mouse model); in tissue culture, ethanolic extracts of Pygeum africanum inhibited the growth of PC-3 and LNCaP cells, induced apoptosis and altered cell kinetics. These findings are preliminary and do not yet have robust clinical corroboration in humans.
Clinical studies have concluded that Pygeum africanum is generally well-tolerated, with mild adverse effects such as diarrhea, nausea, constipation, and headache.
Evidence strength: Moderate preliminary evidence for BPH symptom improvement, primarily from older, small, short-term trials. Endorsed by the European Medicines Agency for traditional use. Larger and longer trials are needed.
5.3 Stinging Nettle Root (Urtica dioica)
Traditional Use: Stinging nettle root preparations have a long history of use in European herbal medicine, particularly in Germany, for urinary and prostate-related complaints. The root (distinct from the leaf) is the part most associated with prostate use and has been included in numerous European phytomedicinal formulations for BPH.
Scientific Evidence: The use of some complementary health approaches such as phytotherapy for the treatment of lower urinary tract symptoms is common. Although there is limited evidence that some phytotherapeutic agents may help improve symptoms related to BPH over the short term, most of the trials conducted have been small in size, of short duration, and used varied doses and preparations.
One double-blind, randomized, placebo-controlled trial specifically evaluated a combination of Pygeum africanum and stinging nettle extracts in patients with benign prostatic hyperplasia; the combination of 25 mg Pygeum africanum and 300 mg stinging nettle extracts produced clinical and urodynamic effects similar to placebo in the study group. This was a single study and does not preclude benefit at different doses or preparation types.
Urtica dioica seems to be generally well-tolerated in clinical trials and may produce mild gastrointestinal effects. A 2015 review noted that Urtica dioica contains tannins, which can interact with concomitant intake of iron, causing a reduction of effects in patients who need iron supplements.
Evidence strength: Weak to inconclusive from controlled trials to date. Often studied in combination with other botanicals. Included in several European phytotherapy preparations but robust standalone RCT evidence is limited.
5.4 Beta-Sitosterol and Plant Sterols
Traditional / Dietary Use: Beta-sitosterol โ a phytosterol found in saw palmetto and many other plant sources including rice bran, wheat germ, corn oils, soybeans, avocados, pecans, and peanuts โ has its own body of clinical evidence for BPH symptoms.
Scientific Evidence: Beta-sitosterol has been studied independently of saw palmetto and shows a somewhat more consistent signal than the whole saw palmetto extract. Several older placebo-controlled trials โ primarily from Germany โ reported improvements in urinary symptom scores and peak urinary flow rates. A Cochrane review of these beta-sitosterol trials (distinct from the saw palmetto Cochrane review) found significant improvements in symptom scores and flow parameters, but noted that the trials were short-term and used different preparations, and that long-term safety and effects on prostate volume or progression were not established. The "beta-sitosterol signal" is stronger than the "saw palmetto alone signal" in older clinical literature, but it still comes with real-world caveats: preparation matters, dosing forms differ, and long-term outcomes remain unestablished.
Evidence strength: Preliminary to moderate from short-term RCTs showing symptomatic benefit for BPH. Longer and larger trials are required to confirm clinical significance and safety.
5.5 Lycopene
Dietary Context: Lycopene is a carotenoid pigment found predominantly in tomatoes and tomato products, as well as in watermelon, pink grapefruit, and papaya. Processed tomato products (tomato sauce, tomato paste) contain lycopene in a form with higher bioavailability due to heat-processing effects. The protective effect of the Mediterranean diet against prostate cancer is also attributed in part to the high consumption of tomato sauce.
Scientific Evidence โ BPH: A 2012 systematic review of eight randomized controlled trials concluded that given the limited number of studies published and their varying quality, it is not possible to support or refute the use of lycopene for the prevention or treatment of BPH or prostate cancer.
Scientific Evidence โ Prostate Cancer: Observational epidemiological data have suggested an inverse association between dietary lycopene intake and prostate cancer risk. In vitro and in vivo experiments show that lycopene not only enhances the antioxidant response of prostate cells but is able to inhibit proliferation, induce apoptosis, and decrease the metastatic capacity of prostate cancer cells. However, there is still no clearly proven clinical evidence supporting the use of lycopene in the prevention or treatment of prostate cancer, due to the only limited number of published randomized clinical trials and the varying quality of existing studies.
In the PROCOMB trial post-hoc analysis, 134 men with lower urinary tract symptoms received doses of 50 mg selenium and 5 mg lycopene for 2 years, but no significant statistical differences were observed in terms of the risk of prostate cancer or mean changes of PSA between the two groups.
There is inadequate data on the safety of lycopene supplements. Lycopene may cause several adverse effects including hypotension and gastrointestinal problems and may increase the risk of bleeding.
Evidence strength: Preclinical and in vitro evidence is promising; observational data is suggestive; clinical trial evidence remains insufficient to draw definitive conclusions. The combination with selenium and saw palmetto (PROCOMB trial) showed improvements in urinary symptom scores but not in prostate cancer incidence.
5.6 Selenium
Dietary Context: Selenium is an essential nonmetal trace element found in grains, meat, poultry, fish, eggs, and dairy products. Earlier observational and smaller intervention studies generated substantial interest in selenium as a potential prostate chemopreventive agent.
Scientific Evidence: The most definitive evidence comes from the large-scale SELECT trial. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was conducted to assess the efficacy of selenium and vitamin E alone, and in combination, on the incidence of prostate cancer. This randomized, double-blind, placebo-controlled, 2ร2 factorial design clinical trial found that neither selenium nor vitamin E reduced the incidence of prostate cancer after seven years, and that vitamin E was associated with a 17% increased risk of prostate cancer compared to placebo.
Over 35,000 men, age 50 and older at the start of the trial, participated in SELECT. The null result was surprising given the strong preclinical and clinical evidence suggesting chemopreventive activity of selenium. Preclinical evidence, as well as findings from the Linxian trials, had suggested that the combination of selenium and vitamin E might offer additional protection.
It is likely that only specific subpopulations may benefit from selenium supplementation; therefore, future studies should consider the baseline selenium status of the participants, age of the cohort, and genotype of specific selenoproteins, among other characteristics.
Evidence strength: Strong negative evidence for supplemental selenium preventing prostate cancer in men who are not selenium-deficient, based on the SELECT mega-trial. Earlier positive signals from observational and smaller trial data have not been confirmed in the definitive RCT.
5.7 Vitamin E
Scientific Evidence: As reported in the SELECT trial, hazard ratios for prostate cancer were 1.17 (99% CI 1.004โ1.36, p=0.008) for vitamin E (400 IU/day of all-rac-ฮฑ-tocopheryl acetate) versus placebo, representing an absolute increase of 1.6 cases per 1,000 person-years. "SELECT has definitively shown a lack of benefit from vitamin E and selenium supplements in the prevention of prostate cancer and has shown there is the potential for harm," according to NCI's Division of Cancer Prevention.
Evidence strength: Strong evidence of harm (increased prostate cancer risk) for supplemental vitamin E at high doses (400 IU/day). This finding represents a major reversal of earlier epidemiological hypotheses and carries significant public health implications.
5.8 Zinc
Dietary Context: Zinc is critical to normal prostate function. A normal prostate has the highest levels of zinc in the body. A 2011 study showed that malignant prostate tissue and prostate tissue from men with BPH had significantly less zinc than normal prostate tissue.
Pumpkin seeds are rich in zinc, a mineral that plays a crucial role in maintaining prostate health. Zinc's contribution to testosterone metabolism and cellular function further substantiates the health benefits of consuming pumpkin seeds as part of a balanced diet, particularly for men over 50.
Scientific Evidence: While the correlation between low tissue zinc and prostatic disease is well-documented, clinical trials of zinc supplementation specifically for prostate health have not produced definitive positive evidence of benefit. Observational data consistently show lower zinc concentrations in diseased prostate tissue, but the direction of causation (whether low zinc contributes to disease or is a consequence of it) remains under investigation.
Evidence strength: Strong associative / mechanistic data; controlled trial evidence for supplemental zinc benefits in prostate conditions remains limited and inconclusive.
5.9 Pumpkin Seed Oil (Cucurbita pepo)
Traditional Use: Pumpkin seeds and their oil have been used in Central European and Balkan folk medicine for generations as a dietary remedy for urinary and prostate complaints. Traditional preparations typically involved consumption of whole seeds or cold-pressed seed oils.
Scientific Evidence: Pumpkin seed oil has shown positive results in the treatment of benign prostatic hyperplasia. That said, researchers are still trying to figure out the mechanism behind how it works. A single-blind randomized clinical trial published in PMC (PMC8527717) evaluated pumpkin seed oil versus tamsulosin for BPH symptom relief and found that pumpkin seed oil relieved BPH symptoms with no side effects, but was not as effective as tamsulosin.
Other clinical interpretations of smaller trials suggest a similar pattern: pumpkin seed oil may reduce obstructive urinary symptoms in men with BPH and perform in a range comparable to other herbal interventions or some medications in limited datasets. The main caveat is that these studies are often small and not always directly comparable, which limits how strong the conclusions can be.
As most findings are preliminary, comprehensive clinical trials are necessary to establish the effectiveness of pumpkin seeds in humans.
Evidence strength: Preliminary, based on small trials. Signals are promising but clinical effect size and mechanisms are not yet established to regulatory standard.
5.10 Green Tea Catechins (GTCs) and EGCG
Traditional Use: Green tea (Camellia sinensis) has been consumed for thousands of years in East Asia. Epidemiological observations noting lower prostate cancer incidence in high green tea-consuming populations (Japan, China) stimulated research interest in its polyphenolic constituents.
Scientific Evidence: One constituent in particular, epigallocatechin-3-gallate (EGCG), has been shown in cell culture models to decrease cell viability and promote apoptosis in multiple cancer cell lines including prostate cancer with no effect on non-cancerous cell lines. The most abundant polyphenol in green tea is EGCG, accounting for 100 to 150 mg in a cup of brewed green tea, and as such has been the focus of preclinical and clinical research.
The cytostatic action of GTCs is reported to be cancer-specific, with EGCG capable of inducing growth arrest in both immortalized prostate epithelial cells and in PCa cells at concentrations that do not cause any toxic effect in normal human prostate epithelial cells. The inhibition of PCa by GTCs and the prevention of tumor progression to the metastatic stage have been consistently documented in animal models by many independent research groups.
In clinical trials, results have been mixed. In a double-blind, placebo-controlled study of 60 Caucasian male volunteers with high-grade prostate intraepithelial neoplasia (HG-PIN), GTC-treated men took three GTC capsules of 200 mg each (total 600 mg/day). After 1 year, only one tumor was diagnosed among the 30 GTC-treated men (incidence rate, 3%), whereas nine tumors were found among the 30 placebo-treated men (incidence rate, 30%).
However, a subsequent US-based placebo-controlled RCT (PMC4596745) of Polyphenon Eยฎ (400 mg EGCG/day) in 97 men with high-grade PIN found that no differences in the number of prostate cancer cases were observed (5/49 PolyE vs. 9/48 placebo, P=0.25). A secondary endpoint comparing PCa plus ASAP among men with HGPIN without ASAP at baseline revealed a decrease in this composite endpoint (3/26 PolyE vs. 10/25 placebo, P<0.024).
The data collected so far suggest that green tea may be a promising agent for PCa chemoprevention and further clinical trials of participants at risk of PCa or early stage PCa are warranted.
Evidence strength: Strong in vitro and preclinical evidence; inconsistent results across clinical trials. The Italian HG-PIN study showed a striking risk reduction, but the larger US replication trial did not confirm the primary endpoint. Evidence is preliminary and warrants further large-scale RCTs.
6. Dietary and Lifestyle Factors
6.1 The Mediterranean Dietary Pattern
Cancers of the large bowel, breast, endometrium, and prostate are also related to high body mass index and high consumption of high-carcinogenic dietary factors such as red and processed meat or saturated fat-rich foods, and to low consumption of vegetables and fruits. Previous meta-analyses suggest that high adherence to the traditional Mediterranean diet pattern provides significant protection from incidence and mortality of cancer of all types. The main component of the Mediterranean diet is olive oil, consumed in high amounts by Mediterranean basin populations. Phenolic compounds exert chemo-preventive effects due to several mechanisms including antioxidant effects and actions on cancer cell signaling, cell cycle progression, and proliferation. The protective effect of the Mediterranean diet against prostate cancer is also attributed to the high consumption of tomato sauce.
6.2 Plant-Based and Vegetable Consumption
High consumption of vegetables, fruits, fish, and whole grain products exerts protective and/or therapeutic effects. Special bioactive functions are assigned to compounds such as flavonoids, stilbenes, and lycopene. Population-level data consistently show that men in countries with high consumption of plant-based diets, including populations in East and South Asia, have substantially lower prostate cancer incidence rates compared with Western populations.
6.3 Physical Activity
The mostly indolent natural history of prostate cancer provides an opportunity for men to explore the benefits of lifestyle interventions. Current evidence suggests appropriate changes in lifestyle including diet, physical activity, and stress reduction with or without dietary supplements may improve both disease outcomes and patient's mental health. A 2024 systematic review and meta-analysis (MDPI, Nutrients, 2024) examining combined physical activity and dietary interventions across cancer types found that a combined intervention of physical activity and nutrition reduced body mass index, body weight, fat mass, insulin, homeostatic model assessment for insulin resistance, C-reactive protein, triglycerides, and depression, while increasing HDL and quality of life scores.
6.4 Obesity and Metabolic Syndrome
Obesity is associated with a higher risk of death from prostate cancer based on the findings of multiple systematic review studies. Mechanisms under investigation include insulin resistance, altered sex hormone levels (particularly lower SHBG and higher free estrogens), and chronic low-grade systemic inflammation associated with adipose tissue.
6.5 Evidence Limitations Across Dietary Research
It is important to note that much of the dietary evidence in prostate health is derived from observational studies, which are subject to confounding and cannot establish causation. As the SELECT mega-trial dramatically demonstrated, positive signals from epidemiological and preclinical work do not always translate into benefits โ and may even yield harms โ in rigorous RCT settings. Limitations of major systematic reviews include evidence derived from meta-analyses of mostly retrospective studies.
7. Summary of Evidence Strength by Ingredient
- Saw palmetto (alone): Negative to neutral in best-quality trials; NCCIH states "probably not helpful" for BPH.
- Pygeum africanum: Modest positive signal in older, smaller RCTs and a Cochrane review; endorsed as a traditional herbal medicine for LUTS by the European Medicines Agency.
- Stinging nettle root: Inconclusive; often studied in combination formulas; controlled trials have not consistently shown benefit.
- Beta-sitosterol: Preliminary to moderate evidence for symptomatic BPH improvement; stronger signal than saw palmetto alone in older literature.
- Lycopene: Strong in vitro evidence; observational epidemiological signals; insufficient and inconsistent clinical trial evidence for definitive conclusions.
- Selenium (supplemental): Definitively shown in SELECT to provide no benefit for prostate cancer prevention; potential harm from excess supplementation.
- Vitamin E (supplemental, high-dose): Shown in SELECT to increase prostate cancer risk by approximately 17% versus placebo โ important safety concern.
- Zinc: Strong associative data; clinical supplementation evidence inconclusive.
- Pumpkin seed oil: Preliminary positive signals for BPH symptom relief; inferior to pharmaceutical therapy; requires larger trials.
- Green tea catechins / EGCG: Consistent and compelling in vitro and animal data; preliminary mixed clinical trial results requiring larger replication.
- Mediterranean diet pattern: Consistent observational evidence of reduced prostate cancer risk and mortality; mechanistically plausible via multiple constituents.
References
Go back